Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Celldex Therapeutics, Inc. (CLDX) had Return on Investments of -17.25% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.01M |
|
$-78.69M |
|
-- |
|
$0.01M |
|
$84.45M |
|
$-84.44M |
|
$5.75M |
|
$-78.69M |
|
$-78.69M |
|
$-78.69M |
|
$-78.69M |
|
$-78.69M |
|
$-78.69M |
|
$-84.44M |
|
$-84.21M |
|
66.57M |
|
66.57M |
|
$-1.18 |
|
$-1.18 |
|
| Balance Sheet Financials | |
$459.22M |
|
$7.40M |
|
$52.03M |
|
$511.25M |
|
$51.47M |
|
-- |
|
$3.56M |
|
$55.03M |
|
$456.23M |
|
$429.04M |
|
$456.23M |
|
66.57M |
|
| Cash Flow Statement Financials | |
$-65.59M |
|
$72.12M |
|
$0.33M |
|
$28.87M |
|
$35.73M |
|
$6.86M |
|
$8.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-562900.00% |
|
-562900.00% |
|
-- |
|
-524566.60% |
|
-524566.60% |
|
$-67.23M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.07 |
|
1380.00 |
|
-17.25% |
|
-18.34% |
|
-15.39% |
|
|
Return on Investments |
-17.25% |
$6.85 |
|
$-1.01 |
|
$-0.99 |
|